Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maryka Quik

Showing results (21-30 of 74) with videos related to

Pageof 8
Sort By:
CNS & Neurological Disorders Drug Targets|August 16, 2011
Targeting nicotinic receptors for Parkinson's disease therapyMaryka Quik, Tanuja Bordia, Luping Huang, et al.
Journal of Neurochemistry|September 3, 2013
Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbensXiomara A Perez, J Michael McIntosh, Maryka Quik
Movement Disorders : Official Journal of the Movement Disorder Society|March 4, 2017
Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian miceXiomara A Perez, Danhui Zhang, Tanuja Bordia, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 5, 2010
Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitizationTanuja Bordia, Carla Campos, J Michael McIntosh, et al.
Experimental Neurology|September 24, 2016
Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesiaTanuja Bordia, Danhui Zhang, Xiomara A Perez, et al.
Pharmacology & Therapeutics|May 20, 2014
Role for the nicotinic cholinergic system in movement disorders; therapeutic implicationsMaryka Quik, Danhui Zhang, Xiomara A Perez, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 29, 2008
Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatumKathryn O'Leary, Neeraja Parameswaran, J Michael McIntosh, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 19, 2014
The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeysDanhui Zhang, Matthew McGregor, Michael W Decker, et al.
International Review of Neurobiology|October 17, 2015
Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement DisordersMaryka Quik, Tanuja Bordia, Danhui Zhang, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|August 24, 2018
Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement DisordersMaryka Quik, James T Boyd, Tanuja Bordia, et al.
Pageof 8

Showing results (21-30 of 74) with videos related to

Sort By:
Pageof 8
CNS & Neurological Disorders Drug Targets|August 16, 2011
Targeting nicotinic receptors for Parkinson's disease therapyMaryka Quik, Tanuja Bordia, Luping Huang, et al.
Journal of Neurochemistry|September 3, 2013
Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbensXiomara A Perez, J Michael McIntosh, Maryka Quik
Movement Disorders : Official Journal of the Movement Disorder Society|March 4, 2017
Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian miceXiomara A Perez, Danhui Zhang, Tanuja Bordia, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 5, 2010
Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitizationTanuja Bordia, Carla Campos, J Michael McIntosh, et al.
Experimental Neurology|September 24, 2016
Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesiaTanuja Bordia, Danhui Zhang, Xiomara A Perez, et al.
Pharmacology & Therapeutics|May 20, 2014
Role for the nicotinic cholinergic system in movement disorders; therapeutic implicationsMaryka Quik, Danhui Zhang, Xiomara A Perez, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 29, 2008
Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatumKathryn O'Leary, Neeraja Parameswaran, J Michael McIntosh, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 19, 2014
The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeysDanhui Zhang, Matthew McGregor, Michael W Decker, et al.
International Review of Neurobiology|October 17, 2015
Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement DisordersMaryka Quik, Tanuja Bordia, Danhui Zhang, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|August 24, 2018
Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement DisordersMaryka Quik, James T Boyd, Tanuja Bordia, et al.
Pageof 8